X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs FRESENIUS KABI ONCO. - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. FRESENIUS KABI ONCO. WOCKHARDT LTD./
FRESENIUS KABI ONCO.
 
P/E (TTM) x -22.0 22.1 - View Chart
P/BV x 2.2 3.1 71.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT LTD.   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
FRESENIUS KABI ONCO.
Mar-13
WOCKHARDT LTD./
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,012176 575.0%   
Low Rs53279 677.1%   
Sales per share (Unadj.) Rs355.937.7 944.3%  
Earnings per share (Unadj.) Rs-60.35.1 -1,183.5%  
Cash flow per share (Unadj.) Rs-46.86.7 -695.5%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.842.5 606.0%  
Shares outstanding (eoy) m110.63158.23 69.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.4 64.2%   
Avg P/E ratio x-12.825.0 -51.2%  
P/CF ratio (eoy) x-16.518.9 -87.2%  
Price / Book Value ratio x3.03.0 100.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,37920,135 424.0%   
No. of employees `0006.31.2 542.9%   
Total wages/salary Rs m9,371703 1,332.6%   
Avg. sales/employee Rs Th6,295.05,176.2 121.6%   
Avg. wages/employee Rs Th1,498.3610.4 245.5%   
Avg. net profit/employee Rs Th-1,066.3699.6 -152.4%   
INCOME DATA
Net Sales Rs m39,3695,963 660.2%  
Other income Rs m1,20218 6,679.4%   
Total revenues Rs m40,5715,981 678.3%   
Gross profit Rs m181,430 1.3%  
Depreciation Rs m1,495258 579.8%   
Interest Rs m2,555-26 -9,826.5%   
Profit before tax Rs m-2,8301,216 -232.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582-68 5,259.8%   
Tax Rs m257342 75.1%   
Profit after tax Rs m-6,669806 -827.5%  
Gross profit margin %024.0 0.2%  
Effective tax rate %-9.128.1 -32.3%   
Net profit margin %-16.913.5 -125.3%  
BALANCE SHEET DATA
Current assets Rs m33,7965,102 662.5%   
Current liabilities Rs m26,9172,385 1,128.4%   
Net working cap to sales %17.545.6 38.4%  
Current ratio x1.32.1 58.7%  
Inventory Days Days79150 52.9%  
Debtors Days Days89113 78.8%  
Net fixed assets Rs m39,6645,148 770.5%   
Share capital Rs m553158 349.7%   
"Free" reserves Rs m27,9686,556 426.6%   
Net worth Rs m28,5226,732 423.7%   
Long term debt Rs m21,731952 2,282.2%   
Total assets Rs m81,62010,388 785.7%  
Interest coverage x-0.1-45.8 0.2%   
Debt to equity ratio x0.80.1 538.7%  
Sales to assets ratio x0.50.6 84.0%   
Return on assets %-5.07.5 -67.1%  
Return on equity %-23.412.0 -195.3%  
Return on capital %-7.714.6 -52.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m9,8075,298 185.1%   
Fx outflow Rs m1,7891,772 100.9%   
Net fx Rs m8,0193,525 227.4%   
CASH FLOW
From Operations Rs m6841,274 53.7%  
From Investments Rs m6,302-1,204 -523.4%  
From Financial Activity Rs m-7,695-196 3,923.9%  
Net Cashflow Rs m-664-126 525.7%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 2.3 0.3 766.7%  
FIIs % 7.7 9.6 80.2%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   67,757 42,599 159.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON LTD  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

WOCKHARDT LTD. Plunges by 6%; BSE HEALTHCARE Index Down 1.5% (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

WOCKHARDT LTD. share price has plunged by 6% and its current market price is Rs 639. The BSE HEALTHCARE is down by 1.5%. The top gainers in the BSE HEALTHCARE Index are BIOCON LTD (up 1.2%) and SANOFI INDIA (up 1.1%). The top losers are WOCKHARDT LTD. (down 6.4%) and SUVEN LIFE (down 5.2%).

WOCKHARDT LTD. Plunges by 6%; BSE HEALTHCARE Index Down 1.5% (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

WOCKHARDT LTD. share price has plunged by 6% and its current market price is Rs 639. The BSE HEALTHCARE is down by 1.5%. The top gainers in the BSE HEALTHCARE Index are BIOCON LTD (up 1.2%) and SYNGENE INTERNATIONAL (up 1.0%). The top losers are WOCKHARDT LTD. (down 6.4%) and SHILPA MEDICARE (down 5.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Sep 21, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS